CD44 and neoplasm: Both Hsp90 inhibitors reduced sphere formation in vitro by decreasing the CD44 and ALDH populations, which were resistant to cisplatin treatment. Additionally, these inhibitors led to a reduction in tumor volume in vivo in cisplatin-resistant models.